Liberate Bio bags key CAR-M patents, eyes first clinical trials in 2026
The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
Their findings, published in the journal Nature, reveal that the spines’ unique porous internal structure allows them to convert water movement into measurable electrical signals
Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results
The trial met its primary endpoint, showing statistically significant improvements in Myasthenia Impairment Index (MGII) Patient-Reported Outcome (PRO) ocular scores at Week 4
The funding will be spread over four years, with BXLS also eligible for regulatory and commercial milestones, plus royalties on worldwide sales
A next-generation, cell-based immunotherapy, CAR-T therapy engineers a patient’s own immune cells to detect and destroy cancer
Recent data reveal that patients undergoing MWL are entering aesthetic practices with unique needs tied to facial structure and skin quality
Subscribe To Our Newsletter & Stay Updated